Finerenone in Diabetic Kidney Disease
DOI:
https://doi.org/10.58931/cdet.2024.2229Abstract
Diabetic kidney disease (DKD) affects 40% of individuals with diabetes mellitus (T2DM) and is associated with an increased risk of cardiovascular events, hospitalization for heart failure, and premature death. Existing treatments focus on lifestyle measures, glycemic control, blood pressure and lipid management, inhibition of the renin‑angiotensin‑aldosterone system (RAAS), and the use of sodium glucose cotransporter 2 inhibitors (SGLT2-i). However, substantial residual risk of progression to end-stage kidney disease (ESKD) or cardiovascular complications remain despite optimal therapy. Finerenone, a non-steroidal mineralocorticoid antagonist (MRA), has been shown to reduce important outcomes when added to evidence-based therapies, and is approved by Health Canada as an adjunct to standard of care therapy in adults with chronic kidney disease (CKD) and T2DM to reduce the risk of ESKD and a sustained decrease in estimated glomerular filtration rate (eGFR), cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure.
References
Chu L, Fuller M, Jervis K, et al. Prevalence of chronic kidney disease in type 2 diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study. Clin Ther. 2021:43(9):1558-73. DOI: https://doi.org/10.1016/j.clinthera.2021.07.015
Stone JA, Houlden RL, Lin P, et al. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Cardiovascular protection in people with diabetes. Can J Diabetes. 2018;42(Suppl 1):S162-9. DOI: https://doi.org/10.1016/j.jcjd.2017.10.024
Perkovic V, Jardine MJ, Neal B, et al; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295-2306. DOI: https://doi.org/10.1056/NEJMoa1811744
Kerendia Product Monograph. Bayer Inc. 2022. Accessed July 22, 2024, https://pdf.hres.ca/dpd_pm/00067806.PDF
Di Lullo L, Lavalle C, Scatena A, et al. Finerenone: questions and answers-the four fundamental arguments on the new-born promising non-steroidal mineralocorticoid receptor antagonist. J Clin Med 2023;12(12):3992. DOI: https://doi.org/10.3390/jcm12123992
Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453-63. DOI: https://doi.org/10.1093/eurheartj/eht187
Bakris GL, Agarwal R, Chan JC, et al. Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group. Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial. JAMA. 2015;314(9):884-94. DOI: https://doi.org/10.1001/jama.2015.10081
Bakris GL, Agarwal R, Anker SD, et al; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219-29. DOI: https://doi.org/10.1056/NEJMoa2025845
Pitt B, Filippatos G, Agarwal R, et al; FIGARO-DKD Investigators. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252-63. DOI: https://doi.org/10.1056/NEJMoa2110956
Agarwal R, Filippatos G, Pitt B, et al; FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474-84. Erratum in: Eur Heart J. 2022 May 21;43(20):1989. DOI: https://doi.org/10.1093/eurheartj/ehab777
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102(5S):S1–S127. DOI: https://doi.org/10.1016/j.kint.2022.06.008
American Diabetes Association Professional Practice Committee; 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024. Diabetes Care. 1 January 2024;47 (Supplement 1): S219–S30.
Rossing P, Filippatos G, Agarwal R, et al; FIDELIO-DKD Investigators. Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy. Kidney Int Rep. 2021;7(1):36-45. DOI: https://doi.org/10.1016/j.ekir.2021.10.008
Awadhesh KS, Akrit S, Singh R, et al. Finerenone in diabetic kidney disease: A systematic review and critical appraisal, Diabetes Metab Syndr. 2022; 16(10):102638. DOI: https://doi.org/10.1016/j.dsx.2022.102638
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Canadian Diabetes & Endocrinology Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
